Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel in Participants With Moderate-to-Severe Acne: The Patient Journey
Journal of Drugs in Dermatology · 2024
DOI: 10.36849/jdd.8639 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal of Drugs in Dermatology, 2024. Verfasst von Hilary Baldwin und 7 weiteren Autor:innen. Hauptthemen laut MEDLINE: Acne Vulgaris, Administration, Cutaneous, Benzoyl Peroxide, Dermatologic Agents.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Baldwin, H., Harper, J. C., Zeichner, J. A., Draelos, Z. D., Eichenfield, L. F., Gold, M., Gold, L. S., & Kircik, L. H. (2024). Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel in Participants With Moderate-to-Severe Acne: The Patient Journey. Journal of Drugs in Dermatology. https://doi.org/10.36849/jdd.8639
Vancouver
Baldwin H, Harper JC, Zeichner JA, Draelos ZD, Eichenfield LF, Gold M, et al. Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel in Participants With Moderate-to-Severe Acne: The Patient Journey. Journal of Drugs in Dermatology. 2024. doi:10.36849/jdd.8639
BibTeX
@article{Baldwin2024,
author = {Baldwin, Hilary and Harper, Julie C and Zeichner, Joshua A and Draelos, Zoe D and Eichenfield, Lawrence F and Gold, Michael and Gold, Linda Stein and Kircik, Leon H},
title = {Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel in Participants With Moderate-to-Severe Acne: The Patient Journey},
journal = {Journal of Drugs in Dermatology},
year = {2024},
doi = {10.36849/jdd.8639}
}
EUVIMED